Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer
Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy served at Aimmune until its acquisition by Nestle Health Science in 2020. Before Aimmune, from 2007-2016, he was executive vice president, chief administrative officer, general counsel, and secretary of Codexis, Inc., a company focused on the development of synthetic enzymes for the pharmaceutical and food industries. Earlier in his career, he served in several roles within the legal department at CV Therapeutics. Mr. Sheehy began his career as a corporate and securities lawyer in Silicon Valley representing emerging growth companies and venture funds. Mr. Sheehy received an A.B. in History from Dartmouth College and a J.D. from American University's Washington College of Law.
'Doug brings extensive global legal experience that will strengthen Mirum's capabilities as we continue to grow our commercial business and advance our rare disease pipeline,' said Chris Peetz, chief executive officer at Mirum. 'Doug will be a great addition to Mirum's leadership team, and I look forward to leveraging his experience in guiding transformative growth for the company.'
'Mirum is an impressive company that has established its place as a leader in rare disease, and I am excited to have the opportunity to join the leadership team and contribute to the exciting work underway,' said Doug Sheehy. 'The company has a focused growth strategy and is poised for continued success as it works to make a meaningful difference in the lives of people impacted by rare disease.'
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution/LIVMARLI® (maralixibat) tablets, CHOLBAM® (cholic acid) capsules, and CTEXLI™ (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients 12 months of age and older; in Europe, it is approved for patients with PFIC three months of age and older. Mirum has initiated the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional settings of cholestatic pruritus. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease.
CTEXLI is FDA-approved for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.
Mirum's late-stage pipeline includes two investigational treatments for several rare diseases.
Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2 VISTAS study for primary sclerosing cholangitis (PSC) and Phase 2b VANTAGE study for primary biliary cholangitis. Volixibat has been granted Breakthrough Therapy Designation for the treatment of cholestatic pruritus in patients with PBC. Mirum is also planning for a Phase 2 study evaluating MRM-3379, a PDE4D inhibitor for the treatment of Fragile X syndrome, a rare genetic neurocognitive disorder.
To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
This UK investment trust has a 39% position in Nvidia stock!
Nvidia (NASDAQ: NVDA) recently became the world's first firm to hit a $4trn valuation. Since then, the stock has chugged higher, and the chipmaker is now a $4.23trn behemoth. For context, that extra bit on the end is roughly equivalent to the market cap of AstraZeneca. In other words, Nvidia's recent $230bn rise is almost equal to the market value of the FTSE 100's current biggest beast. Indeed, the AI computing giant is now worth more than the entire FTSE 100 combined, with over $1trn to spare. Let that sink in. Due to its ascent, Nvidia has become tech royalty, and rightly so. These days, it's hard to find a tech-focused fund or investment trust that doesn't hold it. Not doing so risks underperformance, a bit like leaving Erling Haaland out of your fantasy football team. The stock is up around 1,600% over five years! Going all-in Sticking with the fantasy football theme, imagine if you could have three Erling Haalands in your portfolio. Just think of all those extra juicy points you might get. In some ways, that is what Manchester & London Investment Trust (LSE: MNL) has done. In its latest June 2025 factsheet, it had a 38.9% weighting to Nvidia. And 26% and 7.1% of net assets in Microsoft and Broadcom, respectively. That means the trust has nearly three-quarters of its portfolio in just three tech stocks! This trio are central to the AI revolution. Nvidia still dominates with its powerful GPUs, while Broadcom makes custom chips and networking hardware used in AI data centres. Microsoft owns part of ChatGPT and has rolled out AI features like Copilot to boost productivity. This extreme concentration has produced tremendous results, though. In the three years to 1 July, Manchester & London Investment Trust's net asset value surged 131.2%. The period coincides with the release of ChatGPT in November 2022, after which Nvidia's share price took off like a rocket. AI era Of course, this massive concentration also adds risk. If Microsoft, Broadcom and/or Nvidia tank, then the trust would underperform badly. Explaining this lack of portfolio diversification, lead manager Mark Sheppard wrote in September: 'Sadly, we do believe the outstanding winners from the AI era may in time be counted on the fingers of two hands. So what are we meant to do? Diversify to dilute performance? Punish our winners for proving they are elite?' Another risk here is a sudden slowdown in AI investments and spending by companies. This would be acutely felt by Nvidia, whose lofty price-to-earnings ratio of 55 is based on expectations of robust future growth. However, the trust doesn't see this happening. It says the AI era is in its infancy: 'AI offers enormous promise and we think this could be one of the most exciting investment and research periods of the century.' Should I invest? To be honest, I admire this bold approach, and it has certainly delivered the goods for shareholders over the last three years. However, I won't be investing myself because I already own Nvidia shares. Increasing my exposure further would be reckless. Investors looking at the trust have to be really bullish on Nvidia and the AI age. The shares are trading at a 12.8% discount to net asset value, but this is definitely in the high-risk, high-reward camp. The post This UK investment trust has a 39% position in Nvidia stock! appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Ben McPoland has positions in AstraZeneca Plc and Nvidia. The Motley Fool UK has recommended AstraZeneca Plc, Microsoft, and Nvidia. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Sign in to access your portfolio
Wall Street Journal
3 hours ago
- Wall Street Journal
Podcast: Stocks Keep Breaking Records
The Nasdaq composite and S&P 500 rose to fresh highs as progress in trade talks bolstered markets. Plus: Intel shares fell after it reported a wider quarterly loss and announced 15% of staff will be laid off. And Samuel Adams brewer Boston Beer said it expects tariffs to have a more moderate effect on its costs. 🎧 Listen: Danny Lewis hosts the WSJ Minute Briefing podcast.
Yahoo
3 hours ago
- Yahoo
Best Stock to Buy Right Now: Apple vs. Costco Wholesale
Key Points Apple and Costco are arguably two of the finest consumer-facing companies you can put money in. Both companies have slowed in recent years, but have years of steady earnings growth ahead. It's close, but there is a winner due to the valuation gap between the two. 10 stocks we like better than Apple › You'll struggle to find better consumer-facing companies than Apple (NASDAQ: AAPL) and Costco Wholesale (NASDAQ: COST). These two companies have built massive, loyal customer followings, and their stocks have delivered life-changing investment returns over the years on their way to becoming two of the world's largest companies by market cap. While both stocks may struggle to deliver the same level of returns they did in their earlier years, both can still be long-term winners in a stock portfolio. That said, you shouldn't just buy at any price, especially for maturing companies like Apple and Costco Wholesale. So, which is the better buy now? Here is what you need to know. Both companies still have some juice left Apple is a leading smartphone and personal electronics company, renowned for its iOS ecosystem, which has over 2.35 billion active users worldwide. Costco is a leading membership-only big-box warehouse retailer, where members can buy a variety of goods, often sold in bulk quantities. Both companies are well-established in their core businesses, but continue to demonstrate the ability to grow, albeit at a slower pace than in the past. With annual revenue in the billions, it's challenging to maintain high growth rates, but growth remains. Apple continues to slowly increase its user base while also growing by offering a variety of subscription services to its users. Service revenue totaled nearly $53 billion through the first half of this year, up 12.7% year over year. For Costco, there is some growth in merchandise sales as inflation lifts prices higher, but its core growth engine is membership growth. Costco's paid memberships increased by 6.8% year over year in the latest quarter to 79.6 million. Membership dues contribute the majority of the company's profits. Overall, both companies have solid -- if not gigantic -- growth prospects. Analysts estimate that Apple will grow its earnings by an average of 10.6% annually over the long term, compared to about 9% for Costco. The two stocks have performed remarkably similarly over the past decade Despite these companies operating very different businesses, their stock prices have performed similarly over the past 10 years. From a share price standpoint, Costco and Apple have generated nearly identical annualized returns over the past decade, and both have vastly outperformed the S&P 500. Both companies pay small-yielding regular dividends, too. Apple has paid and raised its dividend for 12 consecutive years, while Costco has done the same for 20 years. Their dividend yields are similar, ranging from about 0.4% to 0.5%. However, Costco occasionally pays special dividends, giving it a slight edge for investors who look for dividend income. But one is the better buy right now Analysts currently expect a little more growth from Apple moving forward than from Costco, but it may also be a bit riskier than Costco. Apple has struggled to integrate artificial intelligence (AI) features into its iOS devices. The company has had to revisit the drawing board. However, Apple users tend to be quite loyal, and the iOS ecosystem is very sticky. So, while it may be too soon to panic, Apple needs to get AI right at some point, or it could face disruptive threats from competitors. Despite this, Apple is still the better stock to buy now. Why? Costco's stock returns over the past decade have been driven in part by valuation expansion. In other words, Costco's stock price has expanded faster than its profits. Today, Costco Wholesale trades at a price-to-earnings (P/E) ratio of nearly 54. That's far too high for a business expected to grow earnings at a 9% annualized pace moving forward. Apple isn't a bargain at a P/E ratio of 33, but it is far more attractive, assuming the company delivers double-digit earnings growth as expected. Apple also repurchases massive amounts of its stock, which should help drive earnings growth, even as the company navigates its AI learning curve. Should you invest $1,000 in Apple right now? Before you buy stock in Apple, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Apple wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,774!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,942!* Now, it's worth noting Stock Advisor's total average return is 1,040% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple and Costco Wholesale. The Motley Fool has a disclosure policy. Best Stock to Buy Right Now: Apple vs. Costco Wholesale was originally published by The Motley Fool Sign in to access your portfolio
